Documents
Resources
Learning Center
Upload
Plans & pricing Sign in
Sign Out

Metastatic Pancreatic Cancer – Pipeline Review, H1 2012

VIEWS: 27 PAGES: 119

Metastatic Pancreatic Cancer – Pipeline Review, H1 2012 Summary Global Markets Direct’s, 'Metastatic Pancreatic Cancer - Pipeline Review, H1 2012', provides an overview of the Metastatic Pancreatic Cancer therapeutic pipeline. This report provides information on the therapeutic development for Metastatic Pancreatic Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Metastatic Pancreatic Cancer. 'Metastatic Pancreatic Cancer - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for Metastatic Pancreatic Cancer. - A review of the Metastatic Pancreatic Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Metastatic Pancreatic Cancer pipeline on the basis of route of administration and molecule type. - Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Metastatic

More Info
									Metastatic Pancreatic Cancer – Pipeline Review, H1 2012




     Metastatic Pancreatic Cancer – Pipeline Review, H1
                            2012
                                                                                          Reference Code: GMDHC1641IDB
                                                                                            Publication Date: January 2012




Metastatic Pancreatic Cancer – Pipeline Review, H1 2012                                    GMDHC1641IDB / Pub January 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied                            Page(1)
Metastatic Pancreatic Cancer – Pipeline Review, H1 2012




Table of Contents
Table of Contents ............................................................................................................................................................................... 2
    List of Tables ................................................................................................................................................................................. 6
    List of Figures ................................................................................................................................................................................ 7
Introduction......................................................................................................................................................................................... 8
    Global Markets Direct Report Coverage ........................................................................................................................................ 8
Metastatic Pancreatic Cancer Overview ............................................................................................................................................. 9
Therapeutics Development............................................................................................................................................................... 10
    An Overview of Pipeline Products for Metastatic Pancreatic Cancer........................................................................................... 10
Metastatic Pancreatic Cancer Therapeutics under Development by Companies ............................................................................. 12
Metastatic Pancreatic Cancer Therapeutics under Investigation by Universities/Institutes .............................................................. 15
Late Stage Products ......................................................................................................................................................................... 21
    Comparative Analysis .................................................................................................................................................................. 21
Mid Clinical Stage Products.............................................................................................................................................................. 22
    Comparative Analysis .................................................................................................................................................................. 22
Early Clinical Stage Products ........................................................................................................................................................... 23
    Comparative Analysis .................................................................................................................................................................. 23
Metastatic Pancreatic Cancer Therapeutics – Products under Development by Companies ........................................................... 24
Metastatic Pancreatic Cancer Therapeutics – Products under Investigation by Universities/Institutes ............................................ 26
Companies Involved in Metastatic Pancreatic Cancer Therapeutics Development .......................................................................... 35
    F. Hoffmann-La Roche Ltd. ......................................................................................................................................................... 35
    Amgen Inc. .................................................................................................................................................................................. 36
    Eli Lilly and Company .................................................................................................................................................................. 37
    Infinity Pharmaceuticals, Inc. ....................................................................................................................................................... 38
    FibroGen, Inc. .............................................................................................................................................................................. 39
    Astellas Pharma Inc..................................................................................................................................................................... 40
    Chugai Pharmaceutical Co. Ltd ................................................................................................................................................... 41
    Pfizer Inc...................................................................................................................................................................................... 42
    Celgene Corporation ................................................................................................................................................................... 43
    Bayer AG ..................................................................................................................................................................................... 44
    IMMUNOMEDICS, INC ............................................................................................................................................................... 45
    Oncolytics Biotech Inc. ................................................................................................................................................................ 46
    NanoCarrier Co., Ltd. .................................................................................................................................................................. 47
    Rexahn Pharmaceuticals, Inc. ..................................................................................................................................................... 48
    Oncoscience AG.......................................................................................................................................................................... 49
    MacroGenics, Inc......................................................................................................................................................................... 50
    OncoMed Pharmaceuticals, Inc. .................................................................................................................................................. 51
    Immutep S.A. ............................................................................................................................................................................... 52
    AB Science .................................................................................................................................................................................. 53
    Clovis Oncology, Inc. ................................................................................................................................................................... 54
    Theradex Systems, Inc. ............................................................................................................................................................... 55
Metastatic Pancreatic Cancer – Therapeutics Assessment.............................................................................................................. 56
    Assessment by Monotherapy Products ....................................................................................................................................... 56



Metastatic Pancreatic Cancer – Pipeline Review, H1 2012                                                                                       GMDHC1641IDB / Pub January 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied                                                                                                   Page(2)
Metastatic Pancreatic Cancer – Pipeline Review, H1 2012




    Assessment by Combination Products ........................................................................................................................................ 57
    Assessment by Route of Administration ...................................................................................................................................... 58
    Assessment by Molecule Type .................................................................................................................................................... 60
Drug Profiles..................................................................................................................................................................................... 63
    AMG-479 - Drug Profile ............................................................................................................................................................... 63
        Product Description................................................................................................................................................................. 63
        Mechanism of Action ............................................................................................................................................................... 63
        R&D Progress ......................................................................................................................................................................... 63
    Abraxane - Drug Profile ............................................................................................................................................................... 65
        Product Description................................................................................................................................................................. 65
        Mechanism of Action ............................................................................................................................................................... 65
        R&D Progress ......................................................................................................................................................................... 65
    CP-4126 - Drug Profile ................................................................................................................................................................ 67
        Product Description................................................................................................................................................................. 67
        Mechanism of Action ............................................................................................................................................................... 67
        R&D Progress ......................................................................................................................................................................... 67
    Gemcitabine + Tarceva - Drug Profile ......................................................................................................................................... 69
        Product Description................................................................................................................................................................. 69
        Mechanism of Action ............................................................................................................................................................... 69
        R&D Progress ......................................................................................................................................................................... 69
    IMC-C225 + Gemcitabine - Drug Profile ...................................................................................................................................... 70
        Product Description................................................................................................................................................................. 70
        Mechanism of Action ............................................................................................................................................................... 70
        R&D Progress ......................................................................................................................................................................... 70
    Gemcitabine hydrochloride - Drug Profile .................................................................................................................................... 72
        Product Description................................................................................................................................................................. 72
        Mechanism of Action ............................................................................................................................................................... 72
        R&D Progress ......................................................................................................................................................................... 72
    Gemcitabine + Dalteparin - Drug Profile ...................................................................................................................................... 73
        Product Description................................................................................................................................................................. 73
        Mechanism of Action ............................................................................................................................................................... 73
        R&D Progress ......................................................................................................................................................................... 73
    AMG 479 + Gemzar - Drug Profile .............................................................................................................................................. 75
        Product Description................................................................................................................................................................. 75
        Mechanism of Action ............................................................................................................................................................... 75
        R&D Progress ......................................................................................................................................................................... 75
    Capecitabine + Gemcitabine - Drug Profile ................................................................................................................................. 77
        Product Description................................................................................................................................................................. 77
        Mechanism of Action ............................................................................................................................................................... 77
        R&D Progress ......................................................................................................................................................................... 77
    Gemcitabine - Drug Profile .......................................................................................................................................................... 79
        Product Description................................................................................................................................................................. 79
        Mechanism of Action ............................................................................................................................................................... 79
        R&D Progress ......................................................................................................................................................................... 79


Metastatic Pancreatic Cancer – Pipeline Review, H1 2012                                                                                     GMDHC1641IDB / Pub January 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied                                                                                                  Page(3)
Metastatic Pancreatic Cancer – Pipeline Review, H1 2012




    Abraxane + Gemzar - Drug Profile .............................................................................................................................................. 80
        Product Description................................................................................................................................................................. 80
        Mechanism of Action ............................................................................................................................................................... 80
        R&D Progress ......................................................................................................................................................................... 80
    Gemcitabine + Capecitabine - Drug Profile ................................................................................................................................. 81
        Product Description................................................................................................................................................................. 81
        Mechanism of Action ............................................................................................................................................................... 81
        R&D Progress ......................................................................................................................................................................... 81
    Gemcitabine + Sorafenib - Drug Profile ....................................................................................................................................... 83
        Product Description................................................................................................................................................................. 83
        Mechanism of Action ............................................................................................................................................................... 83
        R&D Progress ......................................................................................................................................................................... 83
    Gemcitabine - Drug P
								
To top